Allevi

Allevi is a pioneering American company revolutionizing the field of 3D bioprinting technology. Their flagship product, the Allevi three bioprinter, empowers researchers and industry professionals to print a wide range of cell lines into intricate geometries for diverse applications. This cutting-edge device features three extruders, enabling the seamless printing of multi-cell tissues with integrated vasculature for enhanced viability. The Allevi three boasts an impressive build volume of 130 x 90 x 60 mm and a temperature-controlled print bed compatible with petri dishes, multi-well plates, and glass slides, facilitating flexible printing processes.

In addition to the Allevi 3, the company's product lineup includes the Allevi one and Allevi six bioprinters, catering to various bioprinting needs. The Allevi 1, launched in 2018, offers a build volume of 91 x 130 x 60 mm and utilizes extrusion bioprinting technology to produce elastomers and bio/organic parts using liquid feedstocks. The Allevi 6, introduced in the same year, also leverages extrusion bioprinting technology to create edible and bio/organic parts from liquid feedstocks.

Allevi seamlessly integrates its hardware offerings with an intuitive software solution, Allevi Bioprint Online, empowering users to design and execute bioprinting experiments effortlessly. As of April 2024, Allevi's innovative solutions have found widespread adoption, with their bioprinters utilized in hundreds of labs globally, contributing to groundbreaking advancements in regenerative medicine and tissue engineering.

In May 2021, Allevi was acquired by the industry leader 3D Systems, further solidifying its position as a frontrunner in the bioprinting landscape. This strategic acquisition positioned 3D Systems at the forefront of advanced bioprinting technologies, enabling the development of proprietary organs-on-chips called h-VIOS for pharmaceutical drug discovery and development.